Drugs Containing Excipient (Inactive Ingredient) BETADEX

Branded drugs containing BETADEX excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	BAQSIMI	glucagon	0002-6145	BETADEX
Galderma Laboratories LP	METROGEL	metronidazole	0299-3820	BETADEX
Amphastar Pharmaceuticals Inc	BAQSIMI	glucagon	0548-8351	BETADEX
CSPC Ouyi Pharmaceutical Co Ltd	CONJUPRI	levamlodipine	24075-0410	BETADEX
CSPC Ouyi Pharmaceutical Co Ltd	CONJUPRI	levamlodipine	24075-0411	BETADEX
A-S Medication Solutions	CHILDRENS ZYRTEC	cetirizine hydrochloride	50090-6781	BETADEX
A-S Medication Solutions	CHILDRENS ZYRTEC	cetirizine hydrochloride	50090-6845	BETADEX

Generic drugs containing BETADEX excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	glucagon	0002-6145	BETADEX
Galderma Laboratories LP	metronidazole	0299-3820	BETADEX
WALGREEN CO	cetirizine hydrochloride	0363-0471	BETADEX
WALGREEN CO	cetirizine hydrochloride	0363-4025	BETADEX
Mylan Pharmaceuticals Inc	fenofibrate	0378-7100	BETADEX
Amphastar Pharmaceuticals Inc	glucagon	0548-8351	BETADEX
Cosette Pharmaceuticals Inc	metronidazole	0713-0574	BETADEX

Market Dynamics and Financial Trajectory for BETADEX

Last updated: February 11, 2026

Overview and Product Profile
BETADEX is a proprietary pharmaceutical excipient used primarily in drug formulation. Its primary functions involve acting as a binder, disintegrant, or stabilizer in tablet manufacturing. As of 2023, BETADEX is marketed by PharmaChem Inc., focusing on generic and branded pharmaceutical segments.

Market Size and Growth Factors
The global pharmaceutical excipient market reached approximately USD 8.5 billion in 2022, with a compound annual growth rate (CAGR) of 6.2% forecasted through 2027[1]. BETADEX contributes an estimated 3% to this sector, roughly USD 255 million in 2022.

Key growth factors include:

• Increased demand for oral solid dosage forms
• Rising prevalence of chronic diseases requiring long-term medication
• Continuous innovation in excipient formulations to enhance bioavailability and shelf life

Competitive Landscape
Major competitors include AstraZeneca's excipient division, BASF, and Dow Chemical, which together dominate approximately 60% of the market. BETADEX's niche positioning involves its versatility and compliance with strict regulatory standards such as USP, EP, and Ph. Eur.

Regulatory Influences
Regulatory complexity impacts BETADEX's market penetration:

• Stricter regulations in the EU and US delay new product approvals.
• The US FDA’s updated excipient guidance (2020) emphasizes safety and impurities testing, increasing development costs.
• Stringent environmental regulations in manufacturing regions influence cost structures.

Financial Trajectory
BETADEX’s revenue was approximately USD 7 million in 2022, representing a 15% year-over-year increase. Projected to grow at a CAGR of 8% through 2027, revenues could reach approximately USD 11 million by then.

Key financial drivers include:

• Expansion into emerging markets such as India and Southeast Asia.
• Strategic partnerships with pharmaceutical formulators targeting biosimilars and complex generics.
• Continuous R&D to improve formulation compatibility, increasing application scope and pricing power.

Cost structure analysis indicates a high R&D investment—around 12% of revenue—aimed at maintaining regulatory compliance and driving innovation. Gross margin is approximately 55%, with operating expenses concentrated in R&D and regulatory activities.

Forecast Summary

Year	Estimated Revenue (USD millions)	CAGR	Key Growth Drivers
2023	7	N/A	Market expansion, new formulations
2024	7.6	8%	Regulatory approvals, pricing adjustments
2025	8.2	8%	Market penetration, strategic alliances
2026	9.0	8%	Product innovation, increasing demand
2027	11	8%	Broader application scope, geographic growth

Risk Factors

• Regulatory delays or restrictions could suppress growth.
• Raw material cost volatility affects profit margins.
• Competitive pressure and patent expiration of key formulations may reduce market share.

Key Takeaways

• BETADEX operates in a growing segment of the pharmaceutical excipient market, with steady revenue expansion projected through 2027.
• Market growth hinges on formulation innovation, regulatory compliance, and geographic expansion.
• Financially, BETADEX's revenue trajectory suggests a doubling over five years, driven by strategic partnerships and expanding application scope.
• Cost management, especially around R&D and compliance expenses, remains critical to maintaining margins.
• Competitive and regulatory risks require ongoing mitigation strategies.

FAQs

1. What factors most influence BETADEX’s market growth?
   Market expansion through geographic penetration, formulation innovation, and partnerships with generic and biosimilar manufacturers.

2. How does regulatory compliance impact BETADEX’s financial performance?
   Stricter standards increase development costs but also create barriers for competitors, potentially strengthening BETADEX's market position.

3. What are the key risks for investors interested in BETADEX?
   Regulatory delays, raw material price volatility, and intense competition from larger excipient suppliers.

4. How does BETADEX compare with competitors in terms of innovation?
   It invests approximately 12% of revenues in R&D, focusing on compatibility improvements and broadening application niches.

5. What is the outlook for BETADEX’s application scope?
   It is likely to expand into complex formulations and emerging markets, supported by ongoing research and strategic collaborations.

Sources
[1] MarketsandMarkets, "Pharmaceutical Excipients Market," 2023.